# Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

> **NCT00862277** · — · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 763 (actual)

## Conditions studied

- Meningococcal Infections
- Meningitis

## Interventions

- **BIOLOGICAL:** Menactra®
- **BIOLOGICAL:** Menomune®

## Key facts

- **NCT ID:** NCT00862277
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-03
- **Final completion:** 2009-12
- **Target enrollment:** 763 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862277, "Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00862277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*